BIIB NASDAQ
Biogen Inc.
1W: -1.0%
1M: -0.3%
3M: -1.3%
YTD: +6.5%
1Y: +45.1%
3Y: -38.4%
5Y: -32.4%
$193.76
+4.29 (+2.26%)
Weekly Expected Move ±5.8%
$171
$182
$193
$204
$215
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.18
Neutral
3 bullish
0 neutral
2 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Why Is Biogen Stock Falling Thursday?
Biogen Completes Acquisition of Apellis Pharmaceuticals
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Trump says unaware of a plan to fire FDA commissioner
Trump to fire FDA commissioner Marty Makary: WSJ
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy
Artiva rises after mid-stage trial data for lead asset in rheumatoid arthritis
Biogen says FDA extends review of Leqembi alzheimer’s injection
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
What's Going On With Replimune Stock On Tuesday?
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Why Biogen Stock Was a Winner on Wednesday
Biogen outlines Apellis deal impacts with $120M-$130M 2026 other income headwind and non-GAAP EPS accretion in 2027
Biogen (BIIB) Q1 2026 Earnings Transcript
All Eyes on Four Key "Mag 7" Earnings Results
Big Boosts to Econ Growth from AI Investment, Inventories & More
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics
Earnings Scheduled For April 29, 2026
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
Biogen Non-GAAP EPS of $3.57 beats by $0.62, revenue of $2.48B beats by $230M
Biogen trims full-year earnings outlook on BD impact
Here are the major earnings before the open Wednesday
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
Biogen Inc. $BIIB Shares Sold by Arizona State Retirement System
Earnings week ahead: MSFT, AAPL, GOOG, AMZN, META, XOM, CVX, KO, V, SBUX, F, GM, and more
AEGON ASSET MANAGEMENT UK Plc Raises Stock Holdings in Biogen Inc. $BIIB
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Biogen Inc. $BIIB Shares Bought by Caprock Group LLC
Biogen Inc. $BIIB Shares Bought by Caprock Group LLC
Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG
Biogen Inc. $BIIB Shares Bought by B. Metzler seel. Sohn & Co. AG
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Biogen (BIIB) Q3 2024 Earnings Transcript
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
Biogen (BIIB) Q2 2025 Earnings Transcript
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Biogen (BIIB) Q3 2025 Earnings Transcript
Align Technology's Q1 Earnings on Deck: Here's What to Expect
FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
Biogen to buy China rights to immune disease drug for up to $850M
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?
Should Value Investors Buy Biogen (BIIB) Stock?
Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman)
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?
BIIB or TECH: Which Is the Better Value Stock Right Now?
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
CEO of top pharma lobby PhRMA to resign: Endpoints News
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Why Biogen (BIIB) Could Beat Earnings Estimates Again
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward
Why Biogen Stock Got Mashed on Monday
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Biogen flags ~$0.19 hit to Q1 net income per share
Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Burns Matteson Capital Management LLC Makes New Investment in Biogen Inc. $BIIB
Econ Financial Services Corp Acquires New Position in Biogen Inc. $BIIB
Why Biogen Stock Sank While the Market Soared on Thursday
Trump Signals Iran Exit, S&P 500 Heads For Worst Month Since September 2022: What's Moving The Market On Tuesday?
Is Trump to blame for delayed drug launches in Europe
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
Biogen Lands Two Fast-Growing Drugs In Blockbuster Apellis Deal
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
U.S. equities rally as Trump signals potential wind-down of Iran war
Apellis surges on $5.6B buyout deal with Biogen
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CoreCap Advisors LLC Purchases 3,077 Shares of Biogen Inc. $BIIB
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
Biogen receives FDA approval for high-dose Spinraza regimen
Generali Investments CEE investicni spolecnost a.s. Purchases 4,797 Shares of Biogen Inc. $BIIB